← Evidence map

ArticleLeukemia & lymphoma2023

The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.

Efrat Luttwak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry. | OpenQuestion